Oxidation and reduction are fundamental reactions; however, these reactions produce reduced or oxidized wastes because of their intrinsic properties. In green chemistry, O2 or H2O2 is used in many oxidations [1, 2, 3, 4, 5], and H2 is used in many reductions [6, 7, 8, 9]. These reactions, which produce no byproducts or only water as a byproduct, are ideal transformations. However, there are many organic transformations that require stoichiometric or super-stoichiometric terminal oxidants such as Cr(VI), Cu(II), periodate, and m-CPBA, or terminal reductants such as nitrites, Zn powder, Fe powder, stannous chloride, and Hantzsch dihydropyridines [10, 11, 12, 13]. In accord with the principles of green chemistry [10, 11, 12, 13, 14, 15, 16], we hypothesized that if an oxidation was combined with a reduction in one pot, the use of oxidants and reductants could be avoided. This would be an ideal method for minimizing waste generation.
Enamides are versatile building blocks in organic synthesis [17, 18, 19, 20, 21, 22, 23, 24]. However, the preparation of enamides involves reductive acylation of ketoximes in the presence of super-stoichiometric Fe powder, PEt3, or NaHSO3 [25, 26, 27, 28, 29]. 1,3-Diynes are useful structures in linearly π-conjugated acetylenic oligomers and nonlinear optical materials [30, 31, 32]. The conventional method for the synthesis of 1,3-diynes is oxidative homocoupling of terminal alkynes in the presence of Ag2O, Me3NO, Cu(II), or O2 [33, 34, 35, 36, 37, 38]. In this paper, we describe a promising example of green organic synthesis, which combines the oxidative coupling of terminal alkynes for 1,3-diyne formation with reductive acylation of ketoximes for enamide preparation in one pot (Scheme 1).
Unless otherwise stated, all reagents and solvents were purchased from commercial suppliers and used without further purification. 1H and 13C NMR spectra were recorded using Varian instruments at 400 and 100 MHz, respectively, with tetramethylsilane as an internal standard. All products were isolated using short chromatography on a silica-gel (200-300 mesh) column, with petroleum ether (60-90 °C) and EtOAc as the eluent, unless otherwise stated. Compounds that had previously been described in the literature were characterized by comparison of their 1H NMR and 13C NMR spectra with the reported data template.
A 25 mL round-bottomed flask charged with ketoxime 1a (67.5 mg, 0.5 mmol), phenylacetylene 2a (102.0 mg, 1.0 mmol), acetic anhydride (102.0 mg, 1.0 mmol), pyridine (47.4 mg, 0.6 mmol), CuI (9.5 mg, 10 mol%), and Pd(PPh3)2Cl2 (0.7 mg, 0.2 mol%) in 1,2-dichloroethane (5.0 mL) was stirred at 120 °C for 5 h under Ar. After completion of the reaction (detected using thin-layer chromatography), the reaction mixture was cooled to room temperature, diluted with EtOAc (10 mL), and washed with H2O (10 mL), brine (10 mL), and CuSO4 (2 mol/L, 5 mL). The organic layers were dried over anhydrous Na2SO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford enamide 3a (77.3 mg, 96% yield) and 1,3-diyne 4a (82.8 mg, 82% yield).
N-(1-Phenylvinyl)acetamide (3a). 1H NMR (400 MHz, CDCl3) δ 7.39-7.34 (m, 6H), 5.78 (s, 1H), 5.07 (s, 1H), 2.04 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.4, 140.5, 138.2, 128.5, 126.0, 102.6, 24.3.
N-[1-(p-Tolyl)vinyl]acetamide (3b). 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 7.2 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 7.10 (s, 1H), 5.77 (s, 1H), 5.04 (s, 1H), 2.35 (s, 3H), 2.07 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.2, 140.4, 138.5, 135.5, 129.3, 125.9, 101.9, 24.4, 21.1.
N-[1-(4-Methoxyphenyl)vinyl]acetamide (3c). 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.0 Hz, 2H), 7.17 (s, 1H), 6.86 (d, J = 8.8 Hz, 2H), 5.69 (s, 1H), 4.99 (s, 1H), 3.79 (s, 3H), 2.06 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.3, 159.8, 140.1, 130.8, 127.3, 113.9, 101.5, 55.3, 24.4.
N-[1-(4-Nitrophenyl)vinyl]acetamide (3d). 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.15 (s, 1H), 5.79 (s, 1H), 5.25 (s, 1H), 2.14 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.2, 147.6, 144.1, 139.2, 126.8, 123.8, 107.1, 24.1.
N-[1-(4-Fluorophenyl)vinyl]acetamide (3e). 1H NMR (400 MHz, CDCl3) δ 7.36-7.33 (t, J = 7.2 Hz, 2H), 7.28 (s, 1H), 7.02-6.98 (t, J = 8.4 Hz, 2H), 5.67 (s, 1H), 4.99 (s, 1H), 2.02 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.3, 162.8 (JCF = 247.2 Hz), 139.7, 134.3, 127.9 (JCF = 8.2 Hz), 115.4 (JCF = 21.4 Hz), 103.1, 24.2.
N-[1-(4-Chlorophenyl)vinyl]acetamide (3f). 1H NMR (400 MHz, CDCl3) δ 7.31 (s, 5H), 5.70 (s, 1H), 5.06 (s, 1H), 2.06 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.4, 139.6, 136.5, 134.4, 128.7, 127.4, 103.7, 24.2.
N-[1-(4-Bromophenyl)vinyl]acetamide (3g). 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 7.11 (s, 1H), 5.73 (s, 1H), 5.07 (s, 1H), 2.08 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.2, 139.6, 137.0, 131.7, 127.6, 122.6, 103.7, 24.3.
N-[1-(3,4-Dimethylphenyl)vinyl]acetamide (3h). 1H NMR (400 MHz, CDCl3) δ 7.18-7.10 (m, 4H), 5.77 (s, 1H), 5.04 (s, 1H), 2.27 (s, 3H), 2.26 (s, 3H), 2.08 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.2, 140.5, 137.2, 136.8, 135.9, 129.8, 127.2, 123.4, 101.6, 24.4, 19.8, 19.5. HRMS Calcd (ESI) m/z for C12H15NNaO: [M + Na]+ 212.1046, found: 212.1050.
N-[1-(5,6,7,8-Tetrahydronaphthalen-2-yl)vinyl]acetamide (3i). 1H NMR (400 MHz, CDCl3) δ 7.14-7.11 (m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 6.87 (s, 1H), 5.82 (s, 1H), 5.03 (s, 1H), 2.77 (s, 4H), 2.12 (s, 3H), 1.80 (s, 4H). 13C NMR (100 MHz, CDCl3) δ 169.0, 140.5, 137.9, 137.4, 135.6, 129.4, 126.5, 123.1, 101.4, 29.4, 29.1, 24.6, 23.0. HRMS Calcd (ESI) m/z for C14H17NNaO: [M + Na]+ 238.1202, found: 238.1207.
N-[1-(2,5-Dimethylphenyl)vinyl]acetamide (3j). 1H NMR (400 MHz, CDCl3) δ 7.16 (s, 1H), 7.09-7.06 (m, 3H), 5.97 (s, 1H), 4.65 (s, 1H), 2.32 (s, 3H), 2.29 (s, 3H), 1.93 (s, 3H).13C NMR (100 MHz, CDCl3) δ 169.0, 140.7, 138.4, 135.3, 132.6, 130.3, 129.8, 129.1, 102.1, 24.2, 20.8, 19.1. HRMS Calcd (ESI) m/z for C12H16NO: [M + H]+ 190.1226, found: 190.1227.
N-[1-(3-Methoxyphenyl)vinyl]acetamide (3k). 1H NMR (400 MHz, CDCl3) δ 7.28-7.24 (m, 2H), 6.98 (d, J = 7.2 Hz, 1H), 6.93 (s, 1H), 6.86 (d, J = 8.0 Hz, 1H), 5.80 (s, 1H), 5.07 (s, 1H), 3.80 (s, 3H), 2.05 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.3, 159.6, 140.4, 139.8, 129.6, 118.4, 113.8, 112.0, 102.6, 55.3, 24.4.
N-[1-(Naphthalen-2-yl)vinyl]acetamide (3l). 1H NMR (400 MHz, CDCl3) δ 7.84-7.82 (m, 4H), 7.54-7.49 (m, 3H), 7.08 (s, 1H), 5.92 (s, 1H), 5.24 (s, 1H), 2.14 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.2, 140.4, 135.5, 133.2, 133.0, 128.4, 128.1, 127.6, 126.5, 126.4, 124.7, 124.0, 103.4, 24.4.
(E)-N-(1-Phenylprop-1-en-1-yl)acetamide (3m). 1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 7.36-7.22 (m, 5H), 5.89-5.87 (m, 1H), 1.99 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.8, 138.4, 134.7, 128.2, 127.2, 125.1, 119.3, 22.7, 13.8.
N-(2-Methyl-1-phenylprop-1-en-1-yl)acetamide (3n). 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.30-7.21 (m, 5H), 1.87 (s, 3H), 1.70 (s, 3H), 1.68 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.5, 139.1, 128.8, 127.7, 127.3, 126.7, 22.7, 20.7, 20.7.
N-(1-Phenylvinyl)propionamide (3o). 1H NMR (400 MHz, CDCl3) δ 7.42-7.32 (m, 5H), 6.96 (s, 1H), 5.87 (s, 1H), 5.07 (s, 1H), 2.36-2.31 (m, 2H), 1.22-1.19 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 172.8, 140.4, 138.5, 128.6, 125.9, 102.2, 30.6, 9.5.
N-(3,4-Dihydronaphthalen-1-yl)acetamide (3p). 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.18-7.12 (m, 4H), 6.26 (s, 1H), 2.72-2.68 (t, J = 8.0 Hz, 2H), 2.32-2.26 (m, 2H), 2.05 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.7, 136.5, 131.6, 131.4, 127.5, 127.2, 126.1, 121.0, 119.8, 27.4, 23.7, 22.0.
N-(6-Methoxy-3,4-dihydronaphthalen-1-yl)acetamide (3q). 1H NMR (400 MHz, CDCl3) δ 7.18 (s, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.73-6.66 (m, 2H), 6.22-6.19 (t, J = 4.4 Hz, 1H), 3.78 (s, 3H), 2.73-2.69 (t, J = 7.6 Hz, 2H), 2.34-2.29 (m, 2H), 2.11 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.4, 158.7, 138.5, 131.3, 124.5, 122.1, 117.2, 113.8, 110.8, 55.1, 28.0, 23.9, 22.1.
N-(1H-Inden-3-yl)acetamide (3r). 1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 7.47 (d, J = 6.8 Hz, 1H), 7.31-7.25 (m, 3H), 6.88 (s, 1H), 3.42 (s, 2H), 2.23 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 168.9, 142.8, 139.7, 135.4, 125.9, 125.4, 124.2, 116.2, 115.7, 36.5, 24.1.
N-(6-Chloro-1H-inden-3-yl)acetamide (3s). 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.48 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.75 (s, 1H), 3.39 (s, 2H), 2.10 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 169.0, 144.6, 139.0, 136.1, 130.1, 125.9, 124.1, 119.6, 114.6, 35.9, 23.5.
N-(Cyclohex-1-en-1-yl)acetamide (3t). 1H NMR (400 MHz, CDCl3) δ 7.19 (s, 1H), 6.05 (s, 1H), 2.19-2.17 (m, 4H), 2.10 (s, 3H), 1.69-1.58 (m, 2H), 1.56-1.55 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 168.7, 132.8, 113.2, 27.8, 24.2, 23.9, 22.4, 21.9.
N-(Cyclopent-1-en-1-yl)acetamide (3u). 1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 5.72 (s, 1H), 2.35-2.31 (m, 2H), 2.27-2.23 (m, 2H), 1.90 (s, 3H), 1.71-1.68 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 173.0, 142.2, 113.3, 38.0, 35.7, 28.5, 25.8.
1,4-Diphenylbuta-1,3-diyne (4a). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.2 Hz, 4H), 7.39-7.36 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 132.5, 129.2, 128.4, 121.7, 81.5, 73.9.
1,4-Di-p-tolylbuta-1,3-diyne (4b). 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.8 Hz, 4H), 7.15 (d, J = 8.0 Hz, 4H), 2.37 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 139.5, 132.3, 129.2, 118.7, 81.5, 73.4, 21.6.
1,4-Bis(4-methoxyphenyl)buta-1,3-diyne (4c). 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.4 Hz, 4H), 6.86 (d, J = 8.8 Hz, 4H), 3.82 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 160.2, 134.0, 114.1, 113.8, 81.2, 72.9, 55.3.
1,4-Bis(4-fluorophenyl)buta-1,3-diyne (4d). 1H NMR (400 MHz, CDCl3) δ 7.56-7.52 (m, 4H), 7.09-7.04 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 163.0 (JCF = 250.5 Hz), 134.5 (JCF = 8.2 Hz), 117.7, 115.9 (JCF = 22.3 Hz), 80.4, 73.5.
1,4-Bis(4-chlorophenyl)buta-1,3-diyne (4e). 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 6.8 Hz, 4H), 7.33 (d, J = 6.4 Hz, 4H).
1,4-Bis(4-bromophenyl)buta-1,3-diyne (4f). 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.0 Hz, 4H), 7.38 (d, J = 8.0 Hz, 4H).
Tetradeca-6,8-diyne (4g). 1H NMR (400 MHz, CDCl3) δ 2.25-2.22 (t, J = 7.2 Hz, 4H), 1.53-1.50 (m, 4H), 1.38-1.29 (m, 8H), 0.91-0.87 (t, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 77.4, 65.2, 30.9, 28.0, 22.1, 19.1, 13.9.
For the green synthesis of enamides and 1,3-diynes, we tried to perform the reductive acylation of ketoximes and oxidative homocoupling of terminal alkynes in one pot to avoid using terminal reductants and oxidants. After several attempts, enamide 3a and 1,3-diyne 4a were obtained in 77% and 59% yields, respectively, in the presence of a [Pd(OAc)2/CuI] catalytic system (Table 1, entry 1). The large difference between the polarities of the enamide and 1,3-diyne makes isolation very easy. This initial result prompted us to optimize the conditions. [Pd(PPh3)2Cl2/CuI] was the most effective catalytic system (Table 1, entries 2-4). Furthermore, organic bases were screened to improve the efficiency (Table 1, entries 5-8). Pyridine was the most effective, and enamide 3a and 1,3-diyne 4a were obtained in 96% and 82% yields, respectively. It should be noted that no reaction occurred when Pd or Cu was used as the sole catalyst, indicating that Pd and Cu catalyzed the reaction synergistically (Table 1, entries 9 and 10).
With the optimized conditions in hand, the scope of this protocol was investigated. This transformation displayed high functional group tolerance and proved to be a general protocol for the simultaneous synthesis of enamides 3 and 1,3-diynes 4. Ketoximes with methyl, methoxy, nitro, and fluoro groups on aryl rings all gave the corresponding enamides 3 and 1,3-diyne 4a in good to excellent yields (Table 2, entries 2-11). Chloro and bromo substituents on the arenes of ketoximes were tolerated well under the conditions used, and no Sonogashira cross- coupling byproducts were observed (Table 2, entries 6 and 7). The ortho-methyl-substituted enamide 3j was obtained in 97% yield, indicating that the transformation was insensitive to steric hindrance (Table 2, entry 10). 2-Naphthyl ketoxime 1l also
reacted smoothly to give the corresponding naphthyl enamide 3l in 60% yield (Table 2, entry 12). The tri- and tetra-substituted enamides 3m and 3n, and 3p-3s, and the N-propyl enamide 3o were also obtained in good yields (Table 2, entries 13-19). Aliphatic ketoximes were also tolerated, to give the corresponding enamides 3t and 3u in moderate yields (Table 2, entries 20 and 21).
Next, various terminal alkynes were examined to extend the substrate scope. A series of 1,3-diynes (4b-4f) with electron-withdrawing or electron-donating groups such as methyl, methoxy, fluoro, chloro, and bromo on aryl rings, and enamide 3a were synthesized in high yields (Table 3, entries 1-5). The aliphatic alkyne 2g also exhibited good reactivity to give 1,3-diyne 4g in 83% yield (Table 3, entry 6).
On the basis of the above experiments and previous studies, a tentative mechanism for the transformation is proposed in Scheme 2. In cycle I, the Cu-catalyzed single-electron reduction of ketoxime acetate A gives an imino radical intermediate B [25, 26, 39, 40, 41, 42, 43, 44]. Further reduction of B, followed by acylation and tautomerization, forms enamide 3 [26, 45, 46]. In cycle II, deprotonation of terminal alkyne 2 in the presence of CuI and pyridine generates a Cu-acetylide intermediate E [33, 34, 35, 36, 37, 38]. Double transmetalation of E with Pd(II) forms a dialkynylpalladium(II) species F. Reductive elimination of F affords the 1,3-diyne 4 and Pd(0) [33, 34, 35, 36, 37, 38, 47, 48, 49, 50]. Finally, Pd(0) was oxidized by Cu2+ to regenerate the active Pd(II) and Cu(I) catalyst, completing cycles I and II.
We have developed a green synthetic protocol for the straightforward synthesis of enamides and 1,3-diynes in one pot in the absence of any terminal oxidants and reductants. The transformation tolerates a range of functional groups and is a novel procedure for the one-pot, high-yielding preparation of valuable enamides and 1,3-diynes. This protocol is a promising method for minimizing reduced or oxidized wastes from both oxidation and reduction reactions. Further study will focus on extending the scope of this green transformation.